CRNX
Crinetics Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Crinetics Pharmaceuticals, Inc. (CRNX) closed at $45.28 as of 2026-02-02, trading 37.2% above its 200-week moving average of $32.99. The stock is currently moving closer to the line, down from 51.9% last week. The 14-week RSI sits at 52, indicating neutral momentum.
Over the past 346 weeks of data, CRNX has crossed below its 200-week moving average 14 times. On average, these episodes lasted 13 weeks. Historically, investors who bought CRNX at the start of these episodes saw an average one-year return of +25.2%.
With a market cap of $4.6 billion, CRNX is a mid-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -44.4%. The stock trades at 4.0x book value.
Share count has increased 95.2% over three years, indicating dilution.
Over the past 6.8 years, a hypothetical investment of $100 in CRNX would have grown to $181, compared to $261 for the S&P 500. CRNX has returned 9.2% annualized vs 15.3% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: CRNX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After CRNX Crosses Below the Line?
Across 14 historical episodes, buying CRNX when it crossed below its 200-week moving average produced an average return of +29.1% after 12 months (median -3.0%), compared to +11.0% for the S&P 500 over the same periods. 40% of those episodes were profitable after one year. After 24 months, the average return was +85.2% vs +36.0% for the index.
Each line shows $100 invested at the moment CRNX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
CRNX has crossed below its 200-week MA 14 times with an average 1-year return of +25.2% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 2019 | Dec 2019 | 27 | 40.0% | -30.4% | +81.1% |
| Jan 2020 | Aug 2021 | 82 | 45.2% | -40.3% | +90.3% |
| Oct 2021 | Oct 2021 | 2 | 4.4% | -10.8% | +132.2% |
| Jan 2022 | Mar 2022 | 10 | 15.5% | +4.4% | +138.7% |
| Apr 2022 | Jul 2022 | 10 | 18.6% | -3.8% | +122.8% |
| Jul 2022 | Aug 2022 | 2 | 4.4% | -4.1% | +132.2% |
| Aug 2022 | Aug 2022 | 1 | 2.6% | -12.5% | +132.0% |
| Sep 2022 | Jan 2023 | 17 | 15.8% | +58.7% | +149.3% |
| Mar 2023 | Apr 2023 | 7 | 17.9% | +144.7% | +162.0% |
| Jun 2023 | Sep 2023 | 12 | 14.8% | +146.2% | +144.6% |
| Mar 2025 | Apr 2025 | 2 | 8.6% | N/A | +68.4% |
| May 2025 | May 2025 | 1 | 0.2% | N/A | +52.2% |
| Jun 2025 | Jul 2025 | 2 | 1.0% | N/A | +51.1% |
| Jul 2025 | Aug 2025 | 2 | 11.4% | N/A | +62.6% |
| Average | 13 | — | +25.2% | — |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02